Johnson & Johnson vs Insulet Corporation
JNJ vs PODD — side-by-side comparison from reported financials. JNJ leads 5, PODD leads 4 of 9 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Insulet Corporation
PODD · Healthcare
$135.28+0.60%Strong
| Metric | JNJ | PODD |
|---|---|---|
| Price | $261.79 | $135.28 |
| Market cap | $631B | $9.38B |
| Revenue (TTM) | $97.9B | $3.05B |
| Revenue growth | +5.6% | +27.5% |
| Net margin | 21.5% | 12.3% |
| Free cash flow | $22.2B | $294M |
| Net cash (debt) | ($27.8B) | ($215M) |
| 1-year price return | +37.0% | -57.8% |
| P/E | 29.9 | 25.0 |
| P/E vs own history (cheap-side %) | 16% | 99% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | 17% |
| Altman Z-score | — | 4.61 |
| CV checks passed | 10 of 11 | 10 of 11 |
| Employees | 140,800 | 5,400 |
Full résumé-style profiles: JNJ CV · PODD CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.